Berno Maaswinkel (born in 1972) is an experienced pharma executive. As a board member for major pharmaceutical companies such as Alcon and Novartis, Berno has a strong track record in building and leading result-oriented teams with a great passion for ophthalmology in the complex and strongly regulated area of drug development.
Berno has led teams in the Netherlands, Belgium and Luxembourg working on various eye diseases such as dry eye, anti infectives, glaucoma, macular degeneration and recently launched the first gene therapy in the Netherlands. Berno has built up a network in the international ophthalmology environment and collaborated with several project teams in Europe to bring solutions to patients with eye disease.
“I often witnessed what losing sight means for patients, some at a very young age. That motivates me to give all my energy to help build ASTHERNA and bring our promising and unique RNA therapies to the market.”